Market cap
$2,862 Mln
Recently Viewed
Clear AllMarket cap
$2,862 Mln
Revenue (TTM)
$-60 Mln
P/E Ratio
--
P/B Ratio
4.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-25.3
Debt to Equity
0
Book Value
$--
EPS
$-3.8
Face value
--
Shares outstanding
50,224,700
CFO
$-323.47 Mln
EBITDA
$-467.57 Mln
Net Profit
$-434.45 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Morphic Holding (MORF)
| 97.3 | 1.9 | 88.5 | 6.7 | -2.2 | 22.0 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Morphic Holding (MORF)
| 8.0 | -43.5 | 41.2 | 95.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate... MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. Read more
President & Interim Principal Executive Officer
Dr. Bruce N. Rogers Ph.D.
President & Interim Principal Executive Officer
Dr. Bruce N. Rogers Ph.D.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Morphic Holding Inc (MORF) is $56.99 (NASDAQ) as of 16-Aug-2024 09:30 EDT. Morphic Holding Inc (MORF) has given a return of -2.16% in the last 3 years.
Since, TTM earnings of Morphic Holding Inc (MORF) is negative, P/E ratio is not available.
The P/B ratio of Morphic Holding Inc (MORF) is 4.63 times as on 30-Aug-2024, a 5 premium to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-7.98
|
1.74
|
|
2022
|
-17.22
|
2.91
|
|
2021
|
-18.10
|
5.07
|
|
2020
|
-23.11
|
7.16
|
|
2019
|
-6.34
|
1.95
|
The 52-week high and low of Morphic Holding Inc (MORF) are Rs -- and Rs -- as of 01-May-2026.
Morphic Holding Inc (MORF) has a market capitalisation of $ 2,862 Mln as on 30-Aug-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Morphic Holding Inc (MORF), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.